Cutaneous mastocytosis treatment: strategies, limitations and perspectives
Open Access
- 1 January 2018
- journal article
- review article
- Published by Termedia Sp. z.o.o. in Advances in Dermatology and Allergology
- Vol. 35 (6) , 541-545
Abstract
Mastocytosis is a rare myeloproliferative disease, characterized by excessive proliferation and accumulation of mast cells in the tissues. In cutaneous mastocytosis (CM), mast cells infiltration is limited to the skin, whereas in systemic mastocytosis (SM) internal organs are involved. The...Keywords
This publication has 43 references indexed in Scilit:
- Drug allergy in mast cell diseaseCurrent Opinion in Allergy and Clinical Immunology, 2012
- Clinical aspects of paediatric mastocytosis: a review of 101 casesJournal of the European Academy of Dermatology and Venereology, 2011
- Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: A phase 2a studyAmerican Journal of Hematology, 2010
- Mastocytosis and insect venom allergyCurrent Opinion in Allergy and Clinical Immunology, 2010
- Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon‐alpha, hydroxyurea, imatinib mesylate or 2‐chlorodeoxyadenosineAmerican Journal of Hematology, 2009
- Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-controlled trialBritish Journal of Dermatology, 2009
- Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patientsAllergy, 2008
- Prevalence of allergy and anaphylactic symptoms in 210 adult and pediatric patients with mastocytosis in Spain: a study of the Spanish network on mastocytosis (REMA)Clinical & Experimental Allergy, 2007
- Ultraviolet Irradiation Induces Apoptosis in Human Immature, But Not in Skin Mast CellsJournal of Investigative Dermatology, 2003
- Treatment of adult systemic mastocytosis with interferon‐α: results of a multicentre phase II trial on 20 patientsBritish Journal of Haematology, 2002